Qin Lin

TL;DR: [68Ga]Ga-DOTA-FAPI-04 PET/CT showed a superior diagnostic efficacy than [18F] FDGPET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer, especially in identifying liver metastases, peritoneal carcinomatosis, and brain tumours.

TL;DR: This study proposed a novel therapeutic regimen that combined programmed death ligand 1 (PD-L1)-based immunotherapy with peptide-based TRT (177Lu as the radionuclide) in the murine colon cancer model and demonstrated that TRT led to an acute increase in PD-L 1 expression on T cells, and TRT in combination with αPD- L1 mAb stimulated the infiltration of CD8+ T cells.

TL;DR: Ga-FAPI PET/CT was performed in a 56-year-old cirrhotic patient with multiple liver nodules, which were suspected of hepatocellular carcinoma by contrast-enhanced magnetic resonance but were not visualized by F-FDG PET/ CT, and features suggestive of benign nodules were found.

TL;DR: This case demonstrates that [Ga]Ga-DOTAFAPI PET is promising and eventually could be more sensitive than [F]FDG; however, well-designed prospective trials with larger patient populations are needed to calculate sensitivity/specificity of this new diagnostic mean.

TL;DR: 18F-FDG uptake in NPC lesions was positively correlated withPD-L1 expression in TCs and negatively correlated with PD-L 1 expression in TIICs, suggesting 18F- FDG PET/CT may be useful for evaluating the PD- L1 status in patients with NPC.